PL2739268T3 - Sposób i formulacja do inhalacji - Google Patents

Sposób i formulacja do inhalacji

Info

Publication number
PL2739268T3
PL2739268T3 PL11870462T PL11870462T PL2739268T3 PL 2739268 T3 PL2739268 T3 PL 2739268T3 PL 11870462 T PL11870462 T PL 11870462T PL 11870462 T PL11870462 T PL 11870462T PL 2739268 T3 PL2739268 T3 PL 2739268T3
Authority
PL
Poland
Prior art keywords
formulation
inhalation method
inhalation
Prior art date
Application number
PL11870462T
Other languages
English (en)
Inventor
Michelle Mcintosh
David Morton
Tomas SOU
Livesey OLERILE
Richard PRANKERD
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903049A external-priority patent/AU2011903049A0/en
Application filed by Monash University filed Critical Monash University
Publication of PL2739268T3 publication Critical patent/PL2739268T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
PL11870462T 2011-08-01 2011-11-07 Sposób i formulacja do inhalacji PL2739268T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011903049A AU2011903049A0 (en) 2011-08-01 Method and formulation for inhalation
EP11870462.6A EP2739268B1 (en) 2011-08-01 2011-11-07 Method and formulation for inhalation
PCT/AU2011/001430 WO2013016754A1 (en) 2011-08-01 2011-11-07 Method and formulation for inhalation

Publications (1)

Publication Number Publication Date
PL2739268T3 true PL2739268T3 (pl) 2019-07-31

Family

ID=47628537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11870462T PL2739268T3 (pl) 2011-08-01 2011-11-07 Sposób i formulacja do inhalacji

Country Status (21)

Country Link
US (3) US20140294969A1 (pl)
EP (1) EP2739268B1 (pl)
CN (1) CN103841960B (pl)
AU (1) AU2011374218B2 (pl)
BR (1) BR112014002646B1 (pl)
CA (1) CA2879317C (pl)
CY (1) CY1121373T1 (pl)
DK (1) DK2739268T3 (pl)
ES (1) ES2708218T3 (pl)
HR (1) HRP20190080T1 (pl)
HU (1) HUE041858T2 (pl)
LT (1) LT2739268T (pl)
MX (1) MX355833B (pl)
PL (1) PL2739268T3 (pl)
PT (1) PT2739268T (pl)
RS (1) RS58456B1 (pl)
SI (1) SI2739268T1 (pl)
SM (1) SMT201900058T1 (pl)
TR (1) TR201900670T4 (pl)
WO (1) WO2013016754A1 (pl)
ZA (1) ZA201401526B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
US9867931B2 (en) 2013-10-02 2018-01-16 Cook Medical Technologies Llc Therapeutic agents for delivery using a catheter and pressure source
BR122019026637B1 (pt) * 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015175961A1 (en) * 2014-05-16 2015-11-19 Stc.Unm Vaccination compositions, methods of making, and methods of use
AU2015338717B2 (en) * 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
US11589603B2 (en) 2015-09-11 2023-02-28 Abbott Laboratories Powdered nutritional product containing branched-chain amino acids and a sugar alcohol
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
PT108885B (pt) 2015-10-12 2019-02-13 Hovione Farm S A Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos
EP3532500A1 (en) 2016-10-31 2019-09-04 Vectura Limited Inhalable powder composition comprising il-13 antibody
JP7680823B2 (ja) * 2017-03-07 2025-05-21 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 吸入可能なニコチン製剤、およびその作製および使用方法
CN111202722A (zh) * 2020-02-13 2020-05-29 江苏艾立康药业股份有限公司 一种洛匹那韦吸入干粉药物组合物及其制备方法
CN111202723A (zh) * 2020-02-15 2020-05-29 江苏艾立康药业股份有限公司 一种达芦那韦吸入干粉药物组合物及其制备方法
CN111202724A (zh) * 2020-02-16 2020-05-29 江苏艾立康药业股份有限公司 一种阿比朵尔吸入干粉药物组合物及其制备方法
KR20230005244A (ko) * 2020-04-20 2023-01-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 생물학적 활성 건조 분말 조성물 및 이의 제조 및 사용 방법
BR112022023464A2 (pt) 2020-06-05 2022-12-20 Cook Medical Technologies Llc Endoscópios médicos para entregar agentes terapêuticos
CN116419754A (zh) * 2020-08-26 2023-07-11 科威里克斯医疗有限公司 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂
WO2023287654A1 (en) 2021-07-14 2023-01-19 Cook Medical Technologies, LLC Systems and methods for preventing clogging of a delivery system
US12496429B2 (en) 2022-10-18 2025-12-16 Cook Medical Technologies Llc Systems and methods for delivering pressurized fluid to a target site alone or in conjunction with therapeutic agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0304540D0 (en) * 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
CA2555841A1 (en) * 2004-02-12 2005-09-01 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20090220435A1 (en) * 2005-07-27 2009-09-03 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
CN101888831A (zh) * 2007-10-05 2010-11-17 哈佛大学的校长及成员们 细胞材料的干粉
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
CN101669925B (zh) * 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju

Also Published As

Publication number Publication date
SMT201900058T1 (it) 2019-02-28
TR201900670T4 (tr) 2019-02-21
HRP20190080T1 (hr) 2019-03-22
SI2739268T1 (sl) 2019-05-31
CN103841960A (zh) 2014-06-04
US20140294969A1 (en) 2014-10-02
EP2739268B1 (en) 2018-10-31
CA2879317C (en) 2019-01-15
MX355833B (es) 2018-05-02
US20220152145A1 (en) 2022-05-19
HUE041858T2 (hu) 2019-05-28
CY1121373T1 (el) 2020-05-29
MX2014001345A (es) 2014-11-13
WO2013016754A1 (en) 2013-02-07
CN103841960B (zh) 2017-07-07
LT2739268T (lt) 2019-03-25
EP2739268A4 (en) 2015-03-25
DK2739268T3 (en) 2019-02-25
RS58456B1 (sr) 2019-04-30
AU2011374218B2 (en) 2017-05-11
AU2011374218A1 (en) 2014-03-20
ZA201401526B (en) 2017-09-27
US12186361B2 (en) 2025-01-07
BR112014002646A2 (pt) 2017-06-13
US20170224762A1 (en) 2017-08-10
EP2739268A1 (en) 2014-06-11
BR112014002646A8 (pt) 2017-06-20
US11065297B2 (en) 2021-07-20
BR112014002646B1 (pt) 2021-09-14
ES2708218T3 (es) 2019-04-09
PT2739268T (pt) 2019-01-28
CA2879317A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
PT2739268T (pt) Método e formulação para inalação
BR112014010450A2 (pt) composição e método
BR112014000238A2 (pt) método e artigo
EP2755720A4 (en) SYSTEMS AND METHODS FOR THE THERAPY OF SLEEP APNEA
PL2734049T3 (pl) Kompozycje probiotyczne i sposoby
PL2704737T3 (pl) Terapeutyczne kompozycje nukleaz i sposoby
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
BR112014009795A2 (pt) método
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112013022766A2 (pt) método de administração de d-pirfenidona e kit
BR112014000015A2 (pt) formulação
EP2731657A4 (en) HUMIDIFIERS
SMT201600465B (it) Dispositivo di inalazione
IT1403906B1 (it) Apparato e metodo per realizzare sbozzati
BR112013022306A2 (pt) método, e, composição
IL231094A0 (en) Fish anesthetic and method
IL227649A0 (en) Insecticidal composition and processes related thereto
BR112014010860A2 (pt) composição e método
EP2770828A4 (en) FORMULATION
BR112013019224A2 (pt) composição, e metodo
IL231798A0 (en) Method and composition
IL231496A0 (en) Hybrid gaming system and method
BR112013022530A2 (pt) método terapêutico homeopático e composições
PL2678714T3 (pl) Dozymetr zdarzeń i powiązane sposoby